Diego Kauffmann‐Guerrero

European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer

PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)

Real-world insights into moderately hypofractionated thoracic radiotherapy in elderly and multimorbid patients with stage II/III NSCLC: a retrospective study

Assessing ChatGPT’s Educational Potential in Lung Cancer Radiotherapy From Clinician and Patient Perspectives: Content Quality and Readability Analysis

Empiric stereotactic body radiotherapy for presumed early-stage lung cancer

1879P Retrospective multicenter analysis of real-world clinical data in patients with PD-L1-negative stage IV non-small cell lung cancer in Germany: “REMARCS-PD-L1-neG

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis

Tumor board simulation improves interdisciplinary decision-making in medical students

1266P Interim analysis from the multicenter ROSE study: Radiation during osimertinib treatment safety and efficacy cohort

1334P PET/CT-guided immune checkpoint blocker treatment discontinuation vs treatment continuation in lung cancer long-term responders: A National Network Genomic Medicine Lung Cancer Germany (nNGM) analysis

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions

Markers of Immune Cell Exhaustion as Predictor of Survival in Surgically-Treated Early-Stage NSCLC

Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations

Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib